Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 70 of the 75 references it cites were found in a registry or an index.

Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases

Abstract

The oxycyclohexyl acid BMS-986278 ( 33 ) is a potent lysophosphatidic acid receptor 1 (LPA 1 ) antagonist, with a human LPA 1 K b of 6.9 nM. The structure–activity relationship (SAR) studies starting from the LPA 1 antagonist clinical compound BMS-986020 ( 1 ), which culminated in the discovery of 33, are discussed. The detailed in vitro and in vivo preclinical pharmacology profiles of 33, as well as its pharmacokinetics/metabolism profile, are described. On the basis of its in vivo efficacy in rodent chronic lung fibrosis models and excellent overall ADME (absorption, distribution, metabolism, excretion) properties in multiple preclinical species, 33 was advanced into clinical trials, including an ongoing Phase 2 clinical trial in patients with lung fibrosis (NCT04308681).

Overview

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.1c01256

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Cited by

See all 62

Metadata

Authors
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., Dhanusu, S., Reddigunta, R., Kumaravel, S., Jusuf, S., Smith, D., Krishnananthan, S., Li, J., Wang, T., Heiry, R., Sum, C. S., Kalinowski, S. S., Hung, C.-P., Chu, C.-H., Azzara, A. V., Ziegler, M., Burns, L., Zinker, B. A., Boehm, S., Taylor, J., Sapuppo, J., Mosure, K., Everlof, G., Guarino, V., Zhang, L., Yang, Y., Ruan, Q., Xu, C., Apedo, A., Traeger, S. C., Cvijic, M. E., Lentz, K. A., Tirucherai, G., Sivaraman, L., Robl, J., Ellsworth, B. A., Rosen, G., Gordon, D. A., Soars, M. G., Gill, M., & Murphy, B. J.
Affiliations
  • Bristol-Myers Squibb (United States) (US)
  • Biocon-Bristol Myers Squibb Research & Development Center, Bangalore 560099, India
  • Cardiovascular & Fibrosis Discovery Biology, Research & Early Development, Bristol Myers Squibb Company, Princeton, New Jersey 08543-4000, United States
Corresponding author
Cheng, Peter T. W.
Venue
Journal of Medicinal Chemistry
Published
2021-10-28
Volume
64
Issue
21
Pages
15549-15581
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W3209712727
Cited by
61
References
75
Citations by year
2026: 11 · 2025: 9 · 2024: 23 · 2023: 13 · 2022: 3 · 2021: 2
FWCI
3.29
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
LPAR1, pulmonary fibrosis, structure-activity relationship, pharmacokinetics, ADME, drug discovery
MeSH terms
Animals, Dose-Response Relationship, Drug, Male, Pulmonary Fibrosis, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Receptors, Lysophosphatidic Acid, Mice, Rats, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01256
The paper
Cheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., Dhanusu, S., Reddigunta, R., Kumaravel, S., Jusuf, S., Smith, D., Krishnananthan, S., Li, J., Wang, T., Heiry, R., . . . Murphy, B. J. (2021). Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.